Showing 1 - 9 of 9 Blood and Lymph Conditions
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) an dCD30-expressing Peripheral T-cell Lymphoma (PTCL) in Older Patients or Patients With Significant Comorbidities Ineligible for Standard Chemotherapy

Status: Enrolling

Investigator: Sai ravi kiran Pingali

Study Coordinator: Juan Morales Viera

Phone: 786.803.2333

This trial will study brentuximab vedotin to find out whether it is an effective treatment for Hodgkin lymphoma (HL) and peripheral T-cell lymphoma (PTCL). Participants in this study will be older or will have other conditions that make them una ... Read more >

A Phase 2, Multicenter, Single-arm Study of Retreatment With Brentuximab Vedotin in Subjects With Relapsed or Refractory Classic Hodgkin Lymphoma (cHL) or CD30-expressing Peripheral T Cell Lymphoma (PTCL)

Status: Enrolling

Investigator: Sai ravi kiran Pingali

Study Coordinator: Juan Morales Viera

Phone: 786.803.2333

This study will look at whether brentuximab vedotin works and is safe in the re-treatment setting. To be in this study, patients must have already received brentuximab vedotin as treatment and have cancer that progressed (got worse) after stoppi ... Read more >

A Phase 3, Randomized, Controlled Study of Prophylactic and On-demand Treatment of cTTP With BAX 930 (rADAMTS13)

Status: Enrolling

Investigator: Lawrence Rice

Study Coordinator: Erin Webb

Phone: 713.441.1111

To purpose of this study is to assess safety and efficacy of BAX 930 in the prevention and treatment of acute episodes of thrombotic thrombocytopenic purpura (TTP) in subjects with severe hereditary deficiency of ADAMTS13 (cTTP; defined as plasm ... Read more >

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Subjects With Pyruvate Kinase Deficiency

Status: Open Not Enrolling

Investigator: Lawrence Rice

Study Coordinator: Erin Webb

Phone: 713.441.1111

Study AG348-C-006 will evaluate the efficacy and safety of orally administered AG-348 as compared with placebo in participants with pyruvate kinase deficiency (PKD), who are not regularly receiving blood transfusions. Participants will be random ... Read more >

A Phase II, Open-label, Prospective, Single-arm, Study to Assess Ability of Eltrombopag to Induce Sustained Remission in Subjects With ITP Who Are Refractory or Relapsed After First-line Steroids

Status: Enrolling

Investigator: Lawrence Rice

Study Coordinator:

Phone:

This study will assess the ability of eltrombopag to induce sustained treatment-free remission in ITP subjects who relapsed or failed to respond to an initial treatment with steroids. There is limited, mainly retrospective evidence that earli ... Read more >

ASTX727 vs IV Decitabine in MDS and CMML

Status: Open Not Enrolling

Investigator: Jasleen Randhawa

Study Coordinator:

Phone:

Multicenter, randomized, open-label, crossover PK study of ASTX727 versus IV decitabine. Adult subjects who are candidates to receive IV decitabine will be randomized 1:1 to receive the ASTX727 tablet Daily×5 in Cycle 1 followed by IV decitabine ... Read more >

COBRA PzF Shield

Status: Open Not Enrolling

Investigator: Alpesh Shah

Study Coordinator:

Phone:

This is a prospective, multi-center, non-randomized, single arm clinical trial that will be conducted at up to 40 sites in the United States and OUS. A minimum of 40% of total patients will be enrolled in the US. This study will enroll patient ... Read more >

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Status: Enrolling

Investigator: Jasleen Randhawa

Study Coordinator: Juan Morales Viera

Phone: 786.803.2333

This partially randomized phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Monoclonal antibod ... Read more >

Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission

Status: Enrolling

Investigator: Sai ravi kiran Pingali

Study Coordinator: Syed Muhammad Saad

Phone: 281.276.5263

This randomized phase III trial studies rituximab after stem cell transplant and to see how well it works compared with rituximab alone in treating patients with in minimal residual disease-negative mantle cell lymphoma in first complete remissi ... Read more >